CLAIMS

1. Use of a pharmaceutical composition comprising a glucocorticoid in the manufacture of a medicament for the treatment of a lymphocyte mediated disease in a subject, wherein the treatment comprises a single acute dose of the pharmaceutical composition to be administered to the subject to deliver the glucocorticoid at a dose equivalent to 9 – 26 mg/kg human equivalent dose (HED) of dexamethasone base,

wherein the pharmaceutical composition comprises one or more pharmaceutically acceptable carriers, and comprises one or more pharmaceutically acceptable preservatives and/or chelating agents;

and wherein the lymphocyte mediated disease is selected from: an autoimmune disease, cancer, residual HIV disease, graft versus host disease, and an allergic disorder.

2. The use according to claim 1, wherein the lymphocyte mediated disease is an allergic disorder, which is asthma.

3. The use according to claim 1, wherein the lymphocyte mediated disease is cancer, which is a germinal centre lymphoma.

4. The use according to claim 1, wherein the lymphocyte mediated disease is cancer, which is a leukemia, a lymphoma, or multiple myeloma.

5. The use according to claim 1, wherein the lymphocyte mediated disease is an autoimmune disease selected from the group consisting of Type 1 diabetes, multiple sclerosis, amyotrophic lateral sclerosis, scleroderma, pemphigus, and lupus.

6. The use according to any one of the preceding claims, wherein the pharmaceutical composition comprises a pharmaceutically acceptable preservative, wherein the pharmaceutically acceptable preservative is a sulfite.

7. The use according to any one of the preceding claims, wherein the pharmaceutical composition comprises a chelating agent, wherein the chelating agent is EDTA.

8. The use according to any one of the preceding claims, wherein the glucocorticoid comprises dexamethasone, optionally wherein the dexamethasone is selected from the group consisting of dexamethasone base, dexamethasone sodium phosphate and dexamethasone acetate.

9. The use according to claim 8, wherein the dexamethasone is dexamethasone sodium phosphate.

10. The use according to any one of the preceding claims, wherein the pharmaceutical composition is to be administered as an intravenous (IV) or oral dose.

11. The use according to any one of the preceding claims, wherein the pharmaceutical composition is to be administered as a single IV dose over 0.25-2 hours.

12. The use according to any one of the preceding claims, wherein the pharmaceutical composition is an aqueous glucocorticoid solution.

13. The use according to any one of the preceding claims, wherein the pharmaceutical composition is to be administered at a dose equivalent to at least 10 mg/kg, at least 11 mg/kg, at least 12 mg/kg, at least 15 mg/kg, at least 18 mg/kg, or at least 24 mg/kg of a human equivalent dose (HED) of dexamethasone base.

14. The use according to any one of the preceding claims, wherein the subject is not co-administered chemotherapy.